Drugs / AD-214
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05914909 | Jul 2023 → Feb 2024 | chronic kidney disease, interstitial lung disease | AdAlta Limited | Completed | No outcome recorded |
| Phase 1 | NCT04494243 | Aug 2020 → Jan 2021 | gastroesophageal reflux disease | Addpharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04415671 | Jun 2020 → Oct 2021 | interstitial lung disease | AdAlta Limited | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05062876 Comparator | Nov 2021 → Mar 2022 | gastroesophageal reflux disease | Addpharma Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AD-214 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05914909 ↗ |
| Action | Inhibit | “antagonise the SDF-1/CXCR4 axis” NCT04415671 ↗ |
| Modality | Protein / enzyme biologic | “AD-214 is a recombinant Fc-fusion protein” NCT04415671 ↗ |
| Route | Intravenous | “When Administered Intravenously” NCT04415671 ↗ |
| Target | CXCR4 | “selectively binds to CXCR4” NCT04415671 ↗ |